Cancer Treatment With Keytruda May Lead to CAD, Case Report Suggests
Treatment with the cancer immunotherapy Keytruda (pembrolizumab) can lead to the development of cold agglutinin disease (CAD), the case of a lung cancer patient demonstrates. The report, “Pembrolizumab-Induced Cold Agglutinin Disease,” was published in the American Journal of Case Reports. While the immune system…